A recent preprint study found that Pfizer’s COVID-19 antiviral Paxlovid may be effective in reducing the risk of developing long COVID in patients recovering from coronavirus infections. The study, funded by the Department of Veterans Affairs (VA), looked through the VA’s health care databases and identified individuals who tested positive for COVID-19 between March and June 2022. Overall, 56,340 participants were included in the study, among whom 9,217 were given Paxlovid within five days of testing positive for SARS-CoV-2, while the remaining 47,123 did not receive any form of COVID-19 antiviral or antibody treatment in the 30 days after their...
